Fresenius Medical Care AG & Co. KGaA Sponsored ADR Forecast, price target & analysts
Fresenius Medical Care AG & Co. KGaA Sponsored ADR Target price 2025 - Analyst rating & recommendation
Fresenius Medical Care AG & Co. KGaA Sponsored ADR Classifications & Recommendation:
Fresenius Medical Care AG & Co. KGaA Sponsored ADR Price Target
| Target Price | $60.73 |
| Price | $24.20 |
| Potential |
150.97%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target Fresenius Medical Care AG & Co. KGaA Sponsored ADR 2026 .
The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR target price is $60.73.
This is
150.97%
register free of charge
$76.01
214.07%
register free of charge
$30.50
26.03%
register free of charge
|
|
| A rating was issued by 25 analysts: 9 Analysts recommend Fresenius Medical Care AG & Co. KGaA Sponsored ADR to buy, 12 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fresenius Medical Care AG & Co. KGaA Sponsored ADR stock has an average upside potential 2026 of
150.97%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 22.58 | 23.11 |
| 0.61% | 2.38% | |
| EBITDA Margin | 15.56% | 18.47% |
| 0.13% | 18.72% | |
| Net Margin | 2.78% | 5.49% |
| 8.46% | 97.34% |
24 Analysts have issued a sales forecast Fresenius Medical Care AG & Co. KGaA Sponsored ADR 2025 . The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR sales estimate is
This results in the following potential growth metrics:
21 Analysts have issued an Fresenius Medical Care AG & Co. KGaA Sponsored ADR EBITDA forecast 2025. The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Fresenius Medical Care AG & Co. KGaA Sponsored ADR Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.14 | 4.33 |
| 7.54% | 102.34% | |
| P/E | 5.59 | |
| EV/Sales | 1.06 |
25 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast for earnings per share. The average Fresenius Medical Care AG & Co. KGaA Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Fresenius Medical Care AG & Co. KGaA Sponsored ADR...
Current Fresenius Medical Care AG & Co. KGaA Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Jun 30 2025 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| MWB RESEARCH AG |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Jun 16 2025 |
| METZLER EQUITIES |
Locked
➜
Locked
|
Locked | May 29 2025 |
| HSBC |
Locked
➜
Locked
|
Locked | May 25 2025 |
| DZ BANK |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jun 30 2025 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
MWB RESEARCH AG:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Jun 16 2025 |
|
Locked
METZLER EQUITIES:
Locked
➜
Locked
|
May 29 2025 |
|
Locked
HSBC:
Locked
➜
Locked
|
May 25 2025 |
|
Locked
DZ BANK:
Locked
➜
Locked
|
May 12 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
